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Hepatocyte growth factor as a renotrophic factor: Significance
in kidney disease
T Nakamura
Osaka University Medical School, Suita, Osaka, Japan
Hepatocyte growth factor (HGF) has been discovered, purified,
and molecularly cloned as a potent mitogen for mature hepato-
cytes. HGF is thought to be a hepatotropic factor which acts as a
trigger for liver regeneration after injury. HGF is a heterodimeric
molecule composed of a 69 kD cr-chain and a 34 kD n-chain which
is linked by a disulfide bridge. Four kringle domains are located
on the cr-chain.
HGF is produced by mesenchymal cells and acts on a wide
variety of epithelial cells. It can function as a mitogen (stimulating
cell growth), motogen (stimulating cell motility), morphogen
(inducing multicellular tissue structure) and tumor suppressor
(suppressing cell growth). These pleiotropic functions of HGF are
essential biological activities for the construction of normal tissue
architecture. Thus, HGF may be one of the long-sought humoral
mediators of morphogenic epithelial-mesenchymal interactions
which are essential for organogenesis. The HGF-receptor has
been identified as the product of the c-met proto-oncogene. This
receptor is a 195 kD transmembrane protein that possesses
tyrosine kinase activities.
HGF mRNA and HGF activity are rapidly and markedly
increased in the liver after various liver injuries. Intravenous
injection of recombinant HGF into mouse remarkably enhanced
liver regeneration in vivo. Moreover, administration of recombi-
nant HGF prevented the onset and progression of hepatic cirrho-
sis in rats and completely abrogated death caused by severe
hepatic cirrhosis. HGF also exerts mitogenic and morphogenic
activities for renal epithelial cells. HGF mRNA in injured kidney
and blood HGF levels were markedly induced after unilateral
nephrectomy and acute renal failure. Exogenously injected HGF
remarkably enhanced renal regeneration in vivo. Intravenous
injection of recombinant HGF into rats with acute renal injury
markedly prevented the onset of severe renal dysfunction and
enhanced the regeneration of the injured kidney. These findings
suggest that HGF, a hepatotrophic factor, also functions as a
renotrophic factor required for renal regeneration. This factor
may be used for effective 'growth factor therapy' in patients with
hepatic and renal dysfunction.
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Among renal cystic disorders, polycystic kidney disease (PKD)
is considered to be the most prevalent and clinically important
inherited disease. The etiology and pathogenesis of PKD still
remain to be defined. Three mechanisms of cystogenesis have
been proposed to cause tubular epithelial cysts: increased tubular
epithelial proliferation, alteration in tubular basement membrane,
and mislocation of the Na/K ATPase pump, resulting in abnor-
malities of ion and fluid secretion.
Recently, several investigators have focused their attention on
hereditary models of PKD which resemble the human disorder.
These include spontaneously occurring and targeted genetic mod-
els of PKD established by transgenic or insertional mutagenesis
techniques. Transgenic mice with a PKD phenotype have been
produced using oncogenes known to be involved in cell prolifer-
ation. Transgenic mice generated with the SV4O early region
develop cysts and glomerulosclerosis associated with proteinuria.
These mice also display renal tubular epithelial hyperplasia,
thymic hyperplasia and lethal choroid plexus tumors. We have
produced a transgenic mouse model of PKD known as SBM. The
transgene consists of the SV40 enhancer, the adult human 13-gb-
bin promoter and the coding region of the c-myc oncogene.
Nineteen transgenic founder mice have been generated.
All SBM founders and mice derived from these founder lines
develop a characteristic PKD phenotype with complete pen-
etrance leading to death from renal failure at six weeks to three
months of age. Histopathologic studies from gestational age to
adulthood have elucidated the evolution of the cystic phenotype.
Renal and glomerular cysts are first detectable in the terminal
stages of renal organogenesis in SBM fetuses. From a young age
(1 to 20 days), transgenic SBM mice develop progressively in-
creasing cyst number and size. In addition, these young SBM mice
have severe epithelial hyperplasia primarily in the proximal
tubules. Fifty percent of young SBM mice develop one or more
microadenomas. Hyperplasia also affected the visceral and pan-
etal epithelium of some glomeruli leading to formation of cres-
cents. Thus, hyperplasia was noted in three related renal epithe-
hum cell types, the proximal tubular, parietal and visceral
epithelium, all of which are derived embryologically from the
proximal metanephric epithelium. In adult SBM mice, the cystic
changes were very severe. Presence of proteinaceous cysts and
interstitial fibrosis were consistently associated with the mature
phenotype. Segmentally or globally sclerotic glomeruli were fre-
quently observed in the kidneys of adult mice but were not a
feature of fetal and young SBM kidneys. Hence, it is likely that
glomerulosclerosis occurs secondary to tubular cysts. These re-
sults suggests that glomeruloscelerosis may arise from at least two
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mechanisms: tubular obstruction or crescent-like glomerular epi-
thelial hyperplasia causing compression of the tuft. Renal function
impairment in adult mice correlated with the severity of the
morphologic renal abnormalities and led to terminal renal failure
by few months of age.
Studies of the transgene expression showed strong expression in
the kidneys and weak or no detectable expression in other organs.
By in situ hybridization analysis, transgene expression was con-
fined to the renal cystic and hyperplastic tubular epithelium in
adult mice, whereas in fetal mice the signal was also detected over
the parietal and visceral epithelium of glomerular cysts.
Definite proof that the SBM transgene is responsible for the
PKD phenotype was obtained by the identification of in vivo
mouse revertants. During the course of continuous breeding of
eight SBM transgenic lines, mice from all these lines underwent
spontaneous mutations consisting of deletions and/or rearrange-
ment of the transgene. A high frequency of spontaneous deletion
of part of the SBM gene was observed in several lines. This high
frequency of mutation appears unrelated to the transgene copy
number or to the site of integration. Revertant mice and their
progeny had no evidence of a renal disease, were healthy and lived
a normal lifespan. This study provides proof that the intact SBM
transgene is necessary and sufficient to produce a PKD pheno-
type.
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Role of growth factors in cell proliferation
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Over the past five years a variety of polypeptide growth factors
have been implicated in the altered cellular proliferation which
accompanies renal tubular cyst formation and progressive en-
largement. Attention has particularly focused on the EGF/TGFa/
EGFR axis in mediating tubular cyst formation. Studies over the
last five years in a number of laboratories have determined that:
(1) EGF and TGFa are cystogenic in vitro; (2) cystic renal tissue
has decreased preproEGF and EGF concentrations but increased
expression of TGFa and EGFR; and (3) renal cyst fluid contains
bioactive and immuoreactive EGF peptides in mitogenic concen-
trations. We have thus chosen to study specific abnormalities of
the EGFR in experimental murine models of ARPKD.
During murine nephrogenesis EGF receptor expression has a
distinct developmental profile by Western analysis. During pro-
gressive stages (newborn through day 21 postnatal) of tubular
cystogenesis in the cpk mouse, EGFR expression was significantly
greater than in matched controls. By immunohistological analysis,
EGFR was present in epithelial basolateral cell membranes in
control collecting tubules, and all but a small population of
immature proximal tubules, at all stages of nephrogenesis. This
contrasts with our previously described pattern of apical-lateral
Na/K ATPase expression during early collecting tubule formation.
While EGFR was expressed basolaterally in cpk proximal tubular
cysts, it was expressed apically as well as basolaterally in the
majority of cystic cpk collecting tubules. The aberrant pattern of
apical EGFR expression was also seen in collecting tubules from
all murine models of collecting tubular cystogenesis currently
under study in our laboratory, as well as in tissue obtained from
patients with ARPKD. To determine whether quantitative and
qualitative abnormalities in EGFR expression were mediated at
the transcription level, steady-state EGFR mRNA expression was
determined at distinct developmental stages in control and cpk
kidneys. Mouse EGFR cDNA was cloned by reverse transcription
of control kidney mRNA followed by PCR amplification. eDNA
was used to generate a specific riboprobe for EGFR mRNA
detection by Northern analysis. Control and cpk kidneys expressed
the same species of EGFR mRNA, ruling out the possibility that
an abnormally spliced variant leads to the production of an
abnormally sorted protein. However, levels of EGFR mRNA
constantly increased with age in cpk kidneys, while remaining
constant in progressive age-matched controls. These data suggest
that there is complex regulation of the EGFR in cystic tubule
epithelium at both the transcriptional and post-transcriptional
levels which may be cell specific. EGFR mislocation and over-
expression may be a mechanism whereby EGF-like factors in
cyst fluid stimulate cellular proliferation through an autocrine-
paracrine cycle in ARPKD.
To participate in such a proposed autocrine-paracrine cycle of
proliferation, apical EGFRs must be able to bind ligand, trans-
duce a signal, and mediate altered proliferation. To identify the
possible physiological significance of apical EGFR expression in
murine models, collecting tubular epithelial cells were isolated
from control and cystic kidneys by direct tubule or cyst microdis-
section followed by selective lectin sorting. DBA positive collect-
ing tubule cells from controls demonstrated mature principle cell
ultrastructural features and basal cell membrane localization of
EGFR. In contrast, DBA positive collecting tubule cells from cpk
cysts demonstrated immature principle cell ultrastructure and
apical expression of EGFR. By Western analysis cpk collecting
tubular cells had increased EGFR. Both control and cpk CT cells
maintain their distinct EGFR expression patterns through at least
10 passages. While both control and cystic collecting tubules
demonstrated similar growth profiles under control conditions,
cpk collecting tubular cells demonstrated a significantly increased
mitogenic response to EGFR supplementation of culture medium
when assessed by tritiated thymidine uptake. Additional studies
were performed on control and cystic collecting tubule popula-
tions grown on culture membrane inserts which permit experi-
mental isolation of apical and basal cell surfaces. Binding of
biotinylated EGF applied to apical cell surfaces was significantly
increased in cpk versus control collecting tubules. In addition,
studies of tyrosine phosphoiylation of the EGFR utilizing immu-
noprecipitation with anti-EGFR followed by Western analysis
with anti-phosphotyrosine antibodies revealed the presence of
phosphorylated EGFR in cpk but not control collecting tubular
cells following application of EGF to apical cell surfaces. On
